CURX · Curanex Pharmaceuticals Inc
$0.19
0.00 (-2.02%)
At close · Jul 29
Going-concern doubt
— cleared May 14, 2026
The latest filing states the doubt was alleviated.
“In prior years, the Company disclosed conditions that raised substantial doubt about its ability to continue as a going concern. Management has re-evaluated the Company's liquidity and capital resources for the twelve-month period from the date of issuance of these unaudited interim financial statements. While certain conditions and events that previously raised substantial doubt may continue to exist, management's plans, including the successful completion of the Company's initial public offering and related capital raising activities, resulting improvement in liquidity, were determined to mitigate the substantial doubt regarding the Company's ability to continue as a going concern. Accordingly, management concluded that no substantial doubt exists about the Company's ability to continue as a going concern.”View the 10-Q filed May 14, 2026
Market Cap
$5.49M
Shares
28.36M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Wanjun Zhang | Chief Financial Officer and Treasurer | Appointed | 2026-01-05 |
| Haiyan Yang | Chief Financial Officer and Treasurer | Resigned | 2026-01-05 |